Company Encyclopedia
View More
name
Seres Therap
MCRB.US
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc.
1.946 T
MCRB.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking258/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE15.95%A
    • Profit Margin1536.75%A
    • Gross Margin-416.24%E
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY121.17%A
    • Total Assets YoY-19.73%E
    • Net Assets YoY82.69%A
  • Cash ScoreD
    • Cash Flow Margin6.51%C
    • OCF YoY0.00%D
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreD
    • Gearing Ratio69.54%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SBI Securities Co. Ltd. Has $39,000 Stake in Seres Therapeutics, Inc. $MCRB

    SBI Securities Co. Ltd. reduced its stake in Seres Therapeutics, Inc. by 95% in Q2, now holding 3,482 shares worth $39,000. Goldman Sachs increased its stake by 40.9% in Q1, owning 74,629 shares valued at $52,000. Seres Therapeutics' stock rose 14.2%, with a market cap of $223.63 million. Analysts have mixed ratings, with a consensus target price of $14.33.

    Market Beat·
    US
    MCRB
    +2.64%
    Market Beat·
    US
    MCRB
    +2.64%

    Insider Selling: Seres Therapeutics (NASDAQ:MCRB) Insider Sells 1,257 Shares of Stock

    Matthew Henn, an insider at Seres Therapeutics, sold 1,257 shares at $17.30 each, totaling $21,746.10. This sale reduced his ownership by 14.31%, leaving him with 7,527 shares valued at $130,217.10. The transaction was disclosed in an SEC filing. Seres Therapeutics' stock price rose to $24.71, with a market cap of $223.55 million. Analysts have mixed ratings on the stock, with a recent price target increase from Canaccord Genuity Group to $22.00. Institutional investors own 59.34% of the company.

    Market Beat·
    US
    MCRB
    +2.64%
    Market Beat·
    US
    MCRB
    +2.64%

    Canaccord Genuity Keeps Their Buy Rating on Seres Therapeutics (MCRB)

    Canaccord Genuity analyst John Newman has reaffirmed a Buy rating on Seres Therapeutics (MCRB) with a price target of $22.00. The overall analyst consensus for Seres Therapeutics is a Moderate Buy, also with a $22.00 average price target. Newman has an average return of -1.6% and a success rate of 36.60%, covering the Healthcare sector.

    Tip Ranks·
    US
    MCRB
    +2.64%
    Tip Ranks·
    US
    MCRB
    +2.64%

    Seres Therap | 10-Q: FY2025 Q3 Revenue: USD 351 K

    LB filings·
    US
    MCRB
    +2.64%
    LB filings·
    US
    MCRB
    +2.64%

    Seres Therapeutics, Inc. SEC 10-Q Report

    Seres Therapeutics, Inc. has released its Q3 2025 Form 10-Q report, revealing total revenue of $0.351 million and a loss from operations of $(22.477) million. The company reported a net income of $8.204 million, driven by a gain from the sale of the VOWST Business. Key developments include the FDA granting Breakthrough Therapy designation to SER-155 and plans for a Phase 2 study. The company is also focusing on cost reduction measures and seeking partnerships to advance its live biotherapeutic candidates.

    TradingView·
    US
    MCRB
    +2.64%
    TradingView·
    US
    MCRB
    +2.64%
    © 2025 Longbridge｜Disclaimer